Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.

ABSTRACT: Twice-weekly carfilzomib (27 mg/m² ) with lenalidomide-dexamethasone (KRd) is a standard-of-care in relapsed or refractory multiple myeloma (RRMM). This phase 1b study evaluated KRd with once-weekly carfilzomib in RRMM. Patients received carfilzomib (30-minute infusion; 56 or 70mg/m² ) on days 1, 8, and 15; lenalidomide 25 mg on days 1-21; and dexamethasone 40 mg on days 1, 8, 15, and 22 (day 22 omitted for cycles 9+) of 28-day cycles. Primary objective was safety/tolerability; efficacy was a secondary objective. Fifty-six RRMM patients enrolled: 22 during dose evaluation (56-mg/m² , n = 10; 70-mg/m² , n = 12) and 34 during dose expansion (all initiated dosing at 70 mg/m² ). After 2 fatal adverse events (AEs) during 70-mg/m²

SUBMITTER: Biran N 

PROVIDER: S-EPMC6593978 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature